UPDATES ON CLPEX.com
Updated the Fingerprint Interest Group web page with FIG #
Inserted KEPT #7 - Error Rates -
The Main Cause: Discuss this topic on CLPEX.com - a discussion has
been created for KEPT.
Michele Triplett brought us
an independent user-review of the
Services Limited (CAS Ltd.) latent print examination proficiency test.
we look at recent
information on the commercialization of fingerprint nanotechnology.
Fingerprint Analysis Nanotechnology Shows Positive Growth
Particles plc (ROAR) developed a nanotechnology-based method used to
uniquely identify chemicals in fingerprints within minutes of analyzing a
sample. The chemicals include nicotine, illicit and prescribed drugs, and a
variety of contact residues, including materials used by terrorists and
criminals. The method has the potential to identify bio-markers, indicating
age, sex, and ethnicity of the fingerprint donor.
ROAR took shape in 2006 when Professor Fred Rowell of the University of
Sunderland wanted to commercialize his fingerprint analysis method. He
serves as Chief Scientific Officer (CSO) of the company. The company
believes that 2008 will be significant in that many law enforcement
agencies, including those in U.S., Australia, and Singapore, will begin to
report positive findings following trials of the company’s fingerprint
ROAR Particles Ltd was formed in 2006 to exploit the technology that was
generated by Professor F Rowell at the University of Sunderland. The
University of Sunderland has a strong focus on nanotechnology and analytical
chemistry. The University has one of the largest single groupings of experts
in the UK, comprising of 3 professors and a further 11 academics.
The Unit is part of the UIC, Centre of Excellence in Nanotechnology, Micro
and Photonics Systems (CENAMPS) set up to commercially exploit excellence
with the five North East Universities.
Description of the Business
ROAR Particles Ltd is involved in the research, development and manufacture
of nanotechnology derived particles for commercial applications. In the
short-medium term (1 - 2 years) the company will concentrate on supplying,
via third-party producers, forensic particles which will be sold in bulk to
licensees globally. In the medium-long term (2 - 5 years) the company will
investigate entry into the Immigration Screening, Employee Screening and
Sports Testing Markets.
Development of Business Ideas
Using a ‘Proof on Concept Grant’ awarded by NStar valued at £90k, ROAR
Particles Ltd, via the University of Sunderland; have developed a range of
stable silica nanoparticles which have embedded in them a variety of dyes
and particles. An obvious commercial application for the technology is the
forensic market place and in particular the profiling of latent
fingerprints. Based on patents taken out by the
University of Sunderland, ROAR Particles Ltd was formed and patent rights
have been transferred to ROAR Particles Ltd for perpetuality, globally and
with the right to sublicense.
Principle Products or Services
ROAR Particles Ltd will offer the following
products and services:
• Nanoparticle powders that will replace
traditional dusting powders that are used to define and profile latent
• Nanoparticles for use in identifying compounds
which may be left on latent fingerprints from human contact e.g. of drug
abuse (cocaine), nicotine and explosives
• Nanoparticles for use in the identification of
endogenous and exogenous metabolites within the structure of fingerprints
e.g. prescribed drugs (anti-epileptics, anti-depressives, anti-psychotics,
• Nanoparticles for skin cell harvesting from
latent print deposits which would be ale to detect and record DNA profiles.
The Management Team
The CEO’s responsibility will cover the company’s
strategy, marketing issues and financing requirements, both short-long term.
Mr J Arend (Chief Executive Officer)
After obtaining his degree from London School of
Economics, Mr Arend joined Richardson Merrell (now part of Procter & Gamble)
and for eight years worked in various marketing capacities up to Director of
Marketing for both OTC and ethical pharmaceuticals in the USA, Australasia
and Europe. Mr Arend joined Rhone Poulenc as a regional general manager
(Asia/South East Asia) in charge of ethical and OTC pharmaceuticals and
later was head of consumer pharmaceuticals for the group. In 1987 he started
an independent consultancy advising emerging biotechnologies on business
planning, business development, strategy, and fund raising. Mr Arend has
been a prime mover and both executive and non-executive director in the
start-up and subsequent flotation of several biotech companies including
Antisoma plc, Osmotech plc, Reflect Technologies plc, Enzacta plc, Doctors
Direct plc and Analytical NanoTechnologies plc.
The CSO’s responsibility will be undertaking
research and development in line with the strategical goals of the company.
Professor Frederick Rowell (Chief Scientific
Professor Rowell has over 34 years of research and
development experience and has specialised in analytical chemistry with an
emphasis of bioreactor technology. He has been the author of over 100
publications in peer reviewed journals and has generated £2.1 million in
research grants from industry, charity and UK/EU governmental and funding
agencies. Professor Rowell has worked with Technia Diagnostics,
International Laboratory Services Ltd, Cambridge Life Sciences plc, World
Health Organisation, Horse Racing Forensic Laboratory and Helena Biosciences
in a consultancy capacity.
From the CLPEX.com Forum:
Does anyone have any information on this nanoparticle powder and how it is
designed to work?
Additional question - has anyone studied the health aspects of nanoparticles
related to latent powder developement?
Keeping Examiners Prepared for Testimony - #7
- The Main Cause
by Michele Triplett, King County
Disclaimer: The intent
of this is to provide thought provoking discussion. No claims of accuracy
Question – Error Rates:
When do most errors occur?
Most errors are in single ID cases.
Most errors are caused by a lack of focus.
Most errors are caused by potential AFIS candidates.
Most errors are caused by inadequate training.
I haven’t seen any published reports with this type of research. The
Dror / Charlton studies do show that bias is one potential cause and the
Bertram / Byrd research has shown that bias is only a problem when an
alternative conclusion is possible (with complex comparisons).
Answers a, b, c, and d: It’s easy to give
possible reasons for errors but during testimony its important separate
speculative information from facts. I’m not aware of any research that
shows why errors occur.
Answer e: This seems to be the best answer. It
states the research that’s been done without overstating its value.
Feel free to pass The Detail along to other
examiners. This is a free newsletter FOR latent print examiners, BY
latent print examiners.
With the exception of weeks such as this week, there
are no copyrights on The Detail content. As always, the website is
open for all to visit!
If you have not yet signed up to receive the
Weekly Detail in YOUR e-mail inbox, go ahead and
join the list now so you don't miss out! (To join this free e-mail
newsletter, enter your name and e-mail address on the following page:
You will be sent a Confirmation e-mail... just click on the link in that
e-mail, or paste it into an Internet Explorer address bar, and you are
signed up!) If you have problems receiving the Detail from a work
e-mail address, there have been past issues with department e-mail filters
considering the Detail as potential unsolicited e-mail. Try
subscribing from a home e-mail address or contact your IT department to
allow e-mails from Topica. Members may unsubscribe at any time.
If you have difficulties with the sign-up process or have been inadvertently
removed from the list, e-mail me personally at
firstname.lastname@example.org and I will try
to work things out.
Until next Monday morning, don't work too hard or too little.
Have a GREAT week!